ALSO NOTED: FDA mulls Gardasil use in 45-and-unders; Inverness to close three plants, cut 395

> The FDA will consider approving Merck's HPV vaccine Gardasil for cancer prevention in women up to 45 years. Release

> Restructuring under the gun of new generics and after being slammed by regulatory defeats, Novartis is bidding adieu to James Shannon, its chief of global drug development. Report

> Device maker Inverness Medical plans to shutter three plants that employ 395 people. Report

> Republican presidential candidate John McCain would cost pharma $40 billion if he gets his way on reimportation, critics say. Report

> The FDA gave its blessing to Baxter's new tissue sealant, Artiss, a slow-setting fibrin product designed for use in skin grafts. Report

> Hormone therapy is often overkill for prostate cancer patients, a new study suggests. Report

> AstraZeneca and Bristol-Myers Squibb may face multiple class-action lawsuits that allege they overcharged for meds that have to be administered by doctors. Report

> A New York Times editorial supports the creation of a government-funded "sales force" to counter one-sided pitches from company reps. Report

> Epix Pharmaceuticals has pulled the plug on its depression drug, saying that a mid-stage trial of PRX-00023 failed to demonstrate sufficient efficacy for major depression. Report

And Finally.. Women who complain of memory loss and fuzzy thinking after chemotherapy may have experienced changes in the brain's "white matter." Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.